<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788697</url>
  </required_header>
  <id_info>
    <org_study_id>BR1-128</org_study_id>
    <nct_id>NCT00788697</nct_id>
  </id_info>
  <brief_title>SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization</brief_title>
  <official_title>Characterization of Focal Liver Lesions With SONOVUE®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the superiority of SonoVue®-enhanced ultrasound
      versus unenhanced ultrasound for characterization of Focal Liver Lesions using final
      diagnosis based on histology or combined imaging/clinical data as truth standard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unit of analysis for the outcome measures was the lesion, equivalent to the subject, since
      each subject had a single lesion that was to be characterized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs), using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-Diagnose (ITD) population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: contrast-enhanced computed tomography (CE CT) and /or contrast-enhanced magnetic resonance imaging (CE-MRI) examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy: Percentage of True Positive and True Negative Among All Lesions</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>The Accuracy of SonoVue-enhanced versus unenhanced ultrasound for characterization of malignant and benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive and true negative lesions/number of total lesions per truth standard) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value (PPV): Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Positive Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per ultrasound) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value (NPV): Percentage of True Negative Lesions Among All Malignant Lesions Per Ultrasound</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Negative Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per ultrasound) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Diagnosis of Malignant FLLs</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of malignant FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Diagnosis of Benign FLLs</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-reader Agreement</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Inter-reader agreement of assessment of malignant or benign by unenhanced and SonoVue-enhanced ultrasonography separately. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized. Computation for the percentage agreement within two categories: &quot;3 out of 3 readers agree&quot; and &quot;2 out of 3 readers agree&quot;.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">349</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Patients who received SonoVue</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with at least 1 target lesion requiring work-up for characterization to undergo
Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;
SonoVue-enhanced ultrasound of the target lesion (CE-US): procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and
Truth standard</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SonoVue-enhanced ultrasound</intervention_name>
    <description>Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)</description>
    <arm_group_label>Patients who received SonoVue</arm_group_label>
    <other_name>sulfur hexafluoride microbubbles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Unenhanced ultrasound</intervention_name>
    <description>-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None</description>
    <arm_group_label>Patients who received SonoVue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female.

          -  Provides written Informed Consent and is willing to comply with protocol requirements.

          -  Is at least 18 years of age.

          -  Has at least 1 focal liver lesion (FLL) (target lesion) requiring work-up for
             characterization. Target lesions may include those:

          -  Incidentally detected,

          -  In subjects with chronic hepatitis or liver cirrhosis,

          -  In subjects with known history of malignancy.

          -  Is scheduled for surgical removal or biopsy of the target lesion from 24 hours to 30
             days after the SonoVue® administration OR

          -  In case tissue biopsy is not indicated nor surgery planned, is scheduled for or has
             performed a contrast-enhanced (CE) CT and/or CE-MRI of the target lesion from 30 days
             to 48 hours prior to or from 24 hours to 30 days after the administration of SonoVue®.

        Exclusion Criteria:

          -  Has an acoustic window insufficient for adequate ultrasound examination of the liver.

          -  Has a FLL that cannot be identified with unenhanced ultrasound.

          -  Has received or is scheduled for antineoplastic chemotherapy or an invasive procedure
             in the time period between test procedures and truth standard assessments which may
             have modified the target lesion.

          -  Is receiving any other contrast medium, within the 48 hours before and up to 24 hours
             following the administration of SonoVue®.

          -  Has previously been enrolled in and completed this study.

          -  Known right to left cardiac shunt, bidirectional or transient.

          -  Has any known allergy to 1 or more of the ingredients of the investigational product
             (sulfur hexafluoride or to any components of SonoVue®).

          -  Has any contraindication to 1 of the planned imaging procedures (ultrasound, CT or
             MRI), e.g., implants, claustrophobia, inadequate medical conditions etc.

          -  Has received an investigational compound within 30 days before admission into this
             study.

          -  Has any medical condition or other circumstances which would significantly decrease
             the chances of obtaining reliable data, achieving study objectives, or completing the
             study and/or post-dose follow-up examinations.

          -  Is determined by the Investigator that the subject is clinically unsuitable for the
             study.

          -  Is a pregnant or lactating female. Exclude the possibility of pregnancy by:

               -  testing on site at the institution serum beta-human chorionic gonadotropin (βHCG)
                  within 24 hours prior to the start of SonoVue® administration,

               -  surgical history (e.g., tubal ligation or hysterectomy),

               -  post menopausal with a minimum 1 year without menses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Luigia Storto, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bracco Diagnostics Inc</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>May 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <disposition_first_submitted>August 18, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 21, 2014</disposition_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Initiation Date (first subject enrolled): 30 September 2009; Study completion date (last patient completed study related activities): 29 January 2013. The study was conducted at 14 investigational sites throughout the United States (USA) and 1 site in Europe.</recruitment_details>
      <pre_assignment_details>A total of 74 patients received SonoVue in the training phase and were included only in safety population. A total of 263 patients received SonoVue in the efficacy phase. The 74 patients, included within the &quot;Not Completed&quot; category below, are the training patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Safety Population</title>
          <description>Interventions included SonoVue administration, unenhanced and SonoVue-enhanced ultrasound and definitive truth standard diagnosis.
Any patient who received SonoVue, training or efficacy phase, regardless of availability of ultrasonography or truth standard, is included in the Safety Population. Twelve patients with “No study drug administered” are not included in the Safety Population.
From 337 patients in the Safety Population, 74 patients enrolled in the training phase were excluded from efficacy analysis, and the Completed patients include efficacy phase patients who underwent SonoVue-enhanced ultrasound (SonoVue CE-US), unenhanced ultrasound (UE-US),and had definite truth standard diagnosis available.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="349"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No study drug administered</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Training Patients</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no truth standard procedure available</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technically inadequate truth standard</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Indeterminate diagnosis from truth stand</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ITD Population</title>
          <description>All patients who received SonoVue and enrolled in the efficacy phase, had a definite final diagnosis from truth standard and unenhanced and SonoVue-enhanced ultrasonography available</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard</title>
        <description>Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs), using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-Diagnose (ITD) population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: contrast-enhanced computed tomography (CE CT) and /or contrast-enhanced magnetic resonance imaging (CE-MRI) examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 240 ITD participants, only 124 participants (lesions) were malignant based on the truth standard and were included for sensitivity.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 – UE-US</title>
            <description>Offsite Reader 1 unenhanced (UE) US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 – UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard</title>
          <description>Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs), using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-Diagnose (ITD) population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: contrast-enhanced computed tomography (CE CT) and /or contrast-enhanced magnetic resonance imaging (CE-MRI) examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100.</description>
          <population>Among the 240 ITD participants, only 124 participants (lesions) were malignant based on the truth standard and were included for sensitivity.</population>
          <units>Percentage of true positive lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Malignant lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="124"/>
                <count group_id="O5" value="124"/>
                <count group_id="O6" value="124"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Malignant lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="124"/>
                <count group_id="O5" value="124"/>
                <count group_id="O6" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" lower_limit="44.4" upper_limit="62.0"/>
                    <measurement group_id="O2" value="64.5" lower_limit="56.1" upper_limit="72.9"/>
                    <measurement group_id="O3" value="41.1" lower_limit="32.5" upper_limit="49.8"/>
                    <measurement group_id="O4" value="60.5" lower_limit="51.9" upper_limit="69.1"/>
                    <measurement group_id="O5" value="66.1" lower_limit="57.8" upper_limit="74.5"/>
                    <measurement group_id="O6" value="46.8" lower_limit="38.0" upper_limit="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0754</p_value>
            <method>McNemar</method>
            <param_type>Difference in Sensitivity (%)</param_type>
            <param_value>11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>23.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>McNemar</method>
            <param_type>Difference in Sensitivity (%)</param_type>
            <param_value>19.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.3</ci_lower_limit>
            <ci_upper_limit>30.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>McNemar</method>
            <param_type>Difference in Sensitivity (%)</param_type>
            <param_value>-19.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.9</ci_lower_limit>
            <ci_upper_limit>-7.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard</title>
        <description>Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 240 ITD participants, only 116 participants (lesions) were benign based on the truth standard and were included for specificity.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 – UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 – UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard</title>
          <description>Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100.</description>
          <population>Among the 240 ITD participants, only 116 participants (lesions) were benign based on the truth standard and were included for specificity.</population>
          <units>Percentage of true negative lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Benign lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="116"/>
                <count group_id="O5" value="116"/>
                <count group_id="O6" value="116"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Benign lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="116"/>
                <count group_id="O5" value="116"/>
                <count group_id="O6" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="16.4" upper_limit="31.9"/>
                    <measurement group_id="O2" value="71.6" lower_limit="63.3" upper_limit="79.8"/>
                    <measurement group_id="O3" value="6.9" lower_limit="2.3" upper_limit="11.5"/>
                    <measurement group_id="O4" value="67.2" lower_limit="58.7" upper_limit="75.8"/>
                    <measurement group_id="O5" value="58.6" lower_limit="49.7" upper_limit="67.6"/>
                    <measurement group_id="O6" value="87.9" lower_limit="82.0" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Specificity (%)</param_type>
            <param_value>47.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.4</ci_lower_limit>
            <ci_upper_limit>57.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Specificity (%)</param_type>
            <param_value>60.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.5</ci_lower_limit>
            <ci_upper_limit>70.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Specificity (%)</param_type>
            <param_value>29.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.7</ci_lower_limit>
            <ci_upper_limit>38.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy: Percentage of True Positive and True Negative Among All Lesions</title>
        <description>The Accuracy of SonoVue-enhanced versus unenhanced ultrasound for characterization of malignant and benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive and true negative lesions/number of total lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>240 participants in the ITD population</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 – UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 – UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy: Percentage of True Positive and True Negative Among All Lesions</title>
          <description>The Accuracy of SonoVue-enhanced versus unenhanced ultrasound for characterization of malignant and benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive and true negative lesions/number of total lesions per truth standard) x 100.</description>
          <population>240 participants in the ITD population</population>
          <units>Percent true positive and negative lesio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Total lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="240"/>
                <count group_id="O6" value="240"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="240"/>
                <count group_id="O5" value="240"/>
                <count group_id="O6" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="33.0" upper_limit="45.3"/>
                    <measurement group_id="O2" value="67.9" lower_limit="62.0" upper_limit="73.8"/>
                    <measurement group_id="O3" value="24.6" lower_limit="19.1" upper_limit="30.0"/>
                    <measurement group_id="O4" value="63.8" lower_limit="57.7" upper_limit="69.8"/>
                    <measurement group_id="O5" value="62.5" lower_limit="56.4" upper_limit="68.6"/>
                    <measurement group_id="O6" value="66.7" lower_limit="60.7" upper_limit="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Accuracy (%)</param_type>
            <param_value>28.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.5</ci_lower_limit>
            <ci_upper_limit>37.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Accuracy (%)</param_type>
            <param_value>39.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.3</ci_lower_limit>
            <ci_upper_limit>47.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3173</p_value>
            <method>McNemar</method>
            <param_type>Difference in Accuracy (%)</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Predictive Value (PPV): Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound</title>
        <description>Positive Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per ultrasound) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 240 ITD participants, the overall number of participants (lesions) assessed as malignant varied based on the evaluation of the UE-US and CE-US made by each off-site Reader.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 – UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 – UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Predictive Value (PPV): Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound</title>
          <description>Positive Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per ultrasound) x 100.</description>
          <population>Among the 240 ITD participants, the overall number of participants (lesions) assessed as malignant varied based on the evaluation of the UE-US and CE-US made by each off-site Reader.</population>
          <units>Percent positive lesions by ultrasound</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Positive lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="113"/>
                <count group_id="O5" value="130"/>
                <count group_id="O6" value="72"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Positive lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="113"/>
                <count group_id="O5" value="130"/>
                <count group_id="O6" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="35.0" upper_limit="50.7"/>
                    <measurement group_id="O2" value="70.8" lower_limit="62.4" upper_limit="79.2"/>
                    <measurement group_id="O3" value="32.1" lower_limit="24.8" upper_limit="39.3"/>
                    <measurement group_id="O4" value="66.4" lower_limit="57.7" upper_limit="75.1"/>
                    <measurement group_id="O5" value="63.1" lower_limit="54.8" upper_limit="71.4"/>
                    <measurement group_id="O6" value="80.6" lower_limit="71.4" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Wald Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative Predictive Value (NPV): Percentage of True Negative Lesions Among All Malignant Lesions Per Ultrasound</title>
        <description>Negative Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per ultrasound) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 240 ITD participants, the overall number of participants (lesions) assessed as benign varied based on the evaluation of the UE-US and CE-US made by each off-site Reader.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 – UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 – UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Predictive Value (NPV): Percentage of True Negative Lesions Among All Malignant Lesions Per Ultrasound</title>
          <description>Negative Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per ultrasound) x 100.</description>
          <population>Among the 240 ITD participants, the overall number of participants (lesions) assessed as benign varied based on the evaluation of the UE-US and CE-US made by each off-site Reader.</population>
          <units>Percent negative lesions by ultrasound</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Negative lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="127"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="168"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Negative lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="127"/>
                <count group_id="O5" value="110"/>
                <count group_id="O6" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="22.7" upper_limit="42.5"/>
                    <measurement group_id="O2" value="65.4" lower_limit="57.1" upper_limit="73.6"/>
                    <measurement group_id="O3" value="9.9" lower_limit="3.4" upper_limit="16.4"/>
                    <measurement group_id="O4" value="61.4" lower_limit="53.0" upper_limit="69.9"/>
                    <measurement group_id="O5" value="61.8" lower_limit="52.7" upper_limit="70.9"/>
                    <measurement group_id="O6" value="60.7" lower_limit="53.3" upper_limit="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7610</p_value>
            <method>Wald Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Diagnosis of Malignant FLLs</title>
        <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of malignant FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 124 ITD participants with malignant lesions based on the truth standard, only 115 participants (lesions) were characterized as either hepatocellular carcinoma (HCC) lesions or metastatic lesions.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 – UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 – UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Diagnosis of Malignant FLLs</title>
          <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of malignant FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
          <population>Among the 124 ITD participants with malignant lesions based on the truth standard, only 115 participants (lesions) were characterized as either hepatocellular carcinoma (HCC) lesions or metastatic lesions.</population>
          <units>Malignant lesions</units>
          <param>Number</param>
          <units_analyzed>Malignant lesions to be characterized</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="115"/>
                <count group_id="O6" value="115"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Malignant lesions to be characterized</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="115"/>
                <count group_id="O6" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of HCC by Truth Standard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="84"/>
                    <measurement group_id="O6" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># HCC(Malignant) Correctly Characterized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of Metastasis by Truth Standard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># Metastasis Correctly Characterized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Diagnosis of Benign FLLs</title>
        <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 116 ITD participants with benign lesions based on the truth standard, only 89 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 – UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 – UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Diagnosis of Benign FLLs</title>
          <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
          <population>Among the 116 ITD participants with benign lesions based on the truth standard, only 89 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.</population>
          <units>Benign lesions</units>
          <param>Number</param>
          <units_analyzed>Benign lesions to be characterized</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="89"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Benign lesions to be characterized</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of Hemangioma by Truth Standard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># Hemangioma Correctly Characterized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of Focal nodular hyperplasia by Truth Standard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>#Focal nodular hyperplasia Correctly Characterized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inter-reader Agreement</title>
        <description>Inter-reader agreement of assessment of malignant or benign by unenhanced and SonoVue-enhanced ultrasonography separately. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized. Computation for the percentage agreement within two categories: “3 out of 3 readers agree” and “2 out of 3 readers agree”.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UE-US</title>
            <description>UE-US Inter-reader agreement</description>
          </group>
          <group group_id="O2">
            <title>CE-US</title>
            <description>CE-US Inter-reader agreement</description>
          </group>
        </group_list>
        <measure>
          <title>Inter-reader Agreement</title>
          <description>Inter-reader agreement of assessment of malignant or benign by unenhanced and SonoVue-enhanced ultrasonography separately. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized. Computation for the percentage agreement within two categories: “3 out of 3 readers agree” and “2 out of 3 readers agree”.</description>
          <units>Percent of total number of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Agreement: All 3 off-site readers agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Agreement: 2 out of 3 off-site readers agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 days after contrast media injection</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a patient or a clinical trial subject administered a medicinal product and that did not necessarily have to have a causal relationship with the use of the product. Any patient who received SonoVue is in the Safety Population.
Of 349 patients who started the study, 12 had &quot;No study drug administered&quot; and are not included and 337 received SonoVue and are included in the Safety Population.
All AEs were categorized using MedDRA 12.1.</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety Population</title>
          <description>Interventions included SonoVue administration, unenhanced and SonoVue-enhanced ultrasound and definitive truth standard diagnosis.
Any patient who received SonoVue, training or efficacy phase, regardless of availability of ultrasonography or truth standard, is included in the Safety Population. Twelve patients with “No study drug administered” are not included in the Safety Population.
Of 349 patients who started the study, 12 patients had &quot;No study drug administered&quot; and are not included and 337 received SonoVue and are included in the Safety Population.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Injection site coldness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphragmalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study results may be presented at scientific symposia or published in a peer-review journal after review by sponsor in accordance with the guidelines set forth in the applicable publication or financial agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Luigia Storto, MD Executive Director X-Ray and Ultrasound Medical Affairs</name_or_title>
      <organization>Bracco Diagnostics Inc.</organization>
      <phone>(609) 514-2200</phone>
      <email>MariaLuigia.Storto@diag.bracco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

